Real world data shows impact of immunotherapy in populations underrepresented in clinical trials, according to JNCCN study
Results are encouraging regarding the benefit of immunotherapy across racial and ethnic groups, but also reinforce need to include more Black and Hispanic people in cancer clinical trials and highlight the importance of equitable treatment delivery for cl
2023-12-11
(Press-News.org) PLYMOUTH MEETING, PA [December 11, 2023] — New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance. The clinical investigators focused on patients in under-represented groups who were typically less likely to be included in the immunotherapy clinical trials that have been conducted to date. They analyzed results from 248 patients treated with pembrolizumab over a 9-year period between January 1, 2013 and June 1, 2022, with non-Hispanic Black, Hispanic, and Non-Hispanic White patients each accounting for an approximately equal percentage. Median overall survival was 16.8 to 26.3 months, similar to results previously reported in large prospective clinical trials.
“There has not been enough information on how immunotherapy affected racially- and ethnically-marginalized patients with lung cancer in the past, because they were not well-represented in most previous studies,” explained lead investigator Matthew Lee, MD, MPH, Assistant Professor of Oncology, Montefiore Einstein Comprehensive Cancer Center (MECCC). “The findings from this study could change how we take care of patients and plan future lung cancer studies to better include all patients. While immunotherapy has significantly improved survival for lung cancer patients overall, differences exist in its administration among individuals of different races and ethnicities. This finding could potentially promote the use of immunotherapy in more diverse patient populations.”
The study results included other notable findings. While race, ethnicity, income, and insurance status did not statistically impact survival, the investigators were surprised to find that higher BMI was associated with longer progression-free survival and shorter time to treatment discontinuation. They also determined that a worse ECOG Performance Status—a standardized tool for measuring how capably a patient can take care of themself, do regular activities, or move around—was significantly more likely to result in poorer outcomes.
“This study highlights the potential importance of adjusting treatment approaches in clinical practice, particularly for patients with a poor ECOG performance status,” said senior researcher Haiying Cheng, MD, PhD, Associate Professor of Oncology and Member of the MECCC Cancer Therapeutics Research Program. “There is a clear need for future studies to include underrepresented patient groups in clinical trials to validate these findings and to better guide clinical practice.”
"This retrospective study provides valuable real-world information on the clinical outcomes of patients from underrepresented racial/ethnic groups undergoing immunotherapy for metastatic NSCLC,” commented Debora S. Bruno MD, MS, Assistant Professor of Medicine - Case Western Reserve University; Medical Director, Dahms Clinical Research Unit, University Hospitals - Cleveland Medical Center, Seidman Cancer Center at Case Comprehensive Cancer Center, who was not involved in this research. “Non-Hispanic Black and Hispanic individuals were gravely underrepresented in registrational immunotherapy trials for lung cancer. As a result, there is a paucity of prospective trial data on the efficacy and safety of this class of antineoplastic agents for such patients.”
Dr. Bruno, a Member of the NCCN Guidelines® Panel for Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas, continued: “While it is certainly reassuring to see a lack of real world racial and ethnic disparities in clinical outcomes when patients receive adequate therapy for their disease, we must continue and strive for equitable representation for all patients in prospective oncology clinical trials."
To read the entire study, visit JNCCN.org. Complimentary access to “Similar Efficacy Observed for First-Line Immunotherapy in Ethnic Minority Patients With Metastatic NSCLC” is available until March 10, 2024.
# # #
About JNCCN—Journal of the National Comprehensive Cancer Network
More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside/BroadcastMed. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit NCCN.org/jnccn/subscribe. Follow JNCCN on Twitter @JNCCN.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-12-11
DOWNLOADABLE VIDEO
MIAMI, FLORIDA (EMBARGOED UNTIL MONDAY, DEC. 11, 2023, AT 2:45 P.M. ET) – Few standard treatments have been available for advanced myelofibrosis, a bone marrow disorder characterized by excessive scar tissue that disrupts the normal production of blood cells
But new research conducted by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating cancer centers indicates that a new type of targeted therapy may ...
2023-12-11
Rotavirus causes gastroenteritis, a condition that includes diarrhea, deficient nutrient absorption and weight loss. Severe cases result in approximately 128,000 deaths annually in infants and children worldwide. Despite intense research on how rotavirus causes diarrhea, there is still no complete answer, but in this new study researchers at Baylor College of Medicine report a new mechanism by which rotavirus induces diarrhea, interfering with the normal absorption of nutrients in the intestine.
The study, published in Proceedings of the National Academy of Sciences, is the first to show that rotavirus-altered lipid metabolism in the intestine plays a ...
2023-12-11
In a world-first, researchers from the GrapheneX-UTS Human-centric Artificial Intelligence Centre at the University of Technology Sydney (UTS) have developed a portable, non-invasive system that can decode silent thoughts and turn them into text.
The technology could aid communication for people who are unable to speak due to illness or injury, including stroke or paralysis. It could also enable seamless communication between humans and machines, such as the operation of a bionic arm or robot.
The ...
2023-12-11
Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year. At the same time, the study shows that remaining on the drug not only promotes additional weight loss but preserves improvements in metabolic and cardiovascular health.
The results from the SURMOUNT-4 study, which appeared Dec. ...
2023-12-11
DALLAS, Dec. 11, 2023 — The American Heart Association — the world’s leading voluntary organization dedicated to a world of longer, healthier lives for all — continues its commitment to address the lack of diversity, equity and inclusion in clinical trials for medical research with the selection of two early-career scientists for the inaugural Robert A. Winn Clinical Investigator Leadership Award in Cardiovascular Research (Winn CILA-CV). The award is sponsored by the Bristol Myers ...
2023-12-11
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting. The combination was generally well-tolerated, a notable finding according to Craig A. Portell, MD, who presented the data for PrECOG, LLC, at the 65th American Society of Hematology (ASH) Meeting and Exposition in San Diego, California, ...
2023-12-11
FOR IMMEDIATE RELEASE
December 11, 2023
ILSI Global press contact:
Katherine Broendel
+1 (202) 659-0074 Ext. 175
kbroendel@ilsi.org
WASHINGTON—The International Life Sciences Institute (ILSI) has announced that its Annual Meeting, Technologies and Climate Change: Shaking up 21st Century Food Systems – Promises and Pitfalls, will take place in Clearwater, Florida, 21-24 January 2024. ILSI's Annual Meeting will feature scientific presentations, professional development and networking opportunities for researchers, academics, industry leaders, nongovernmental organizations, as well as public sector and ...
2023-12-11
Amanda Madden, Assistant Professor, History and Art History; Director, Geospatial History, received funding for the project: "La sfera (The Globe): A Late Medieval World of Merchants, Maps, & Manuscripts."
In collaboration with the project team, Co-PI Madden, Senior Developer Jason Heppler, and the Roy Rosenzweig Center for History and New Media (RRCHNM) propose to design and develop a digital edition of the text, including the user interface and data pipeline.
The NEH grant will fund the development of a dynamic, interactive ...
2023-12-11
Scientists are developing an experiment to test whether gravity is quantum
In quantum mechanics, which describes the behaviour of atoms and molecules –objects behave differently to everything we know: they can be in a quantum superposition of being in two places at the same time
Now, scientists are investigating a way to determine whether gravity operates in this way, by levitating micro diamonds in a vacuum
If gravity is quantum, it will ‘entangle’ the diamonds – an intriguing phenomenon which strongly links two objects in ways impossible in everyday life
This research will help ...
2023-12-11
BUFFALO, N.Y. – University at Buffalo research has identified how a misstep in the genesis of a key component of the kidney causes infantile cystinosis, a rare disease that significantly shortens the lifespan of patients. Published Nov. 30 in the International Journal of Molecular Sciences, the work reveals that the mechanisms that cause the disease could be addressed and potentially cured through the genome-editing technique CRISPR. That could make kidney transplants, the most effective treatment currently available for these patients, unnecessary.
Infantile ...
LAST 30 PRESS RELEASES:
[Press-News.org] Real world data shows impact of immunotherapy in populations underrepresented in clinical trials, according to JNCCN study
Results are encouraging regarding the benefit of immunotherapy across racial and ethnic groups, but also reinforce need to include more Black and Hispanic people in cancer clinical trials and highlight the importance of equitable treatment delivery for cl
